Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SNY 
Sanofi ADR (SNY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: SNY (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $63.87
1 Year Target Price $63.87
| 5 | Strong Buy |
| 3 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1.05% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 119.44B USD | Price to earnings Ratio 16.8 | 1Y Target Price 63.87 |
Price to earnings Ratio 16.8 | 1Y Target Price 63.87 | ||
Volume (30-day avg) 11 | Beta 0.41 | 52 Weeks Range 43.86 - 57.57 | Updated Date 07/2/2025 |
52 Weeks Range 43.86 - 57.57 | Updated Date 07/2/2025 | ||
Dividends yield (FY) 4.58% | Basic EPS (TTM) 2.92 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.95% | Operating Margin (TTM) 20.78% |
Management Effectiveness
Return on Assets (TTM) 4.28% | Return on Equity (TTM) 7.3% |
Valuation
Trailing PE 16.8 | Forward PE 10.2 | Enterprise Value 132682387562 | Price to Sales(TTM) 2.64 |
Enterprise Value 132682387562 | Price to Sales(TTM) 2.64 | ||
Enterprise Value to Revenue 2.51 | Enterprise Value to EBITDA 11.2 | Shares Outstanding 2435069952 | Shares Floating 1129022239 |
Shares Outstanding 2435069952 | Shares Floating 1129022239 | ||
Percent Insiders - | Percent Institutions 10.48 |
Upturn AI SWOT
Sanofi ADR
Company Overview
History and Background
Sanofi ADR traces its roots back to 1999, resulting from the merger of Sanofi and Synthu00e9labo. Over time, it has grown through strategic acquisitions and internal research and development, becoming a major global pharmaceutical company.
Core Business Areas
- Pharmaceuticals: Focuses on prescription medications across various therapeutic areas, including diabetes, cardiovascular, immunology, and oncology.
- Vaccines: Develops and manufactures vaccines for a range of infectious diseases under the Sanofi Pasteur brand.
- Consumer Healthcare: Offers over-the-counter medications and health products for self-care needs.
Leadership and Structure
Sanofi is led by a CEO and operates under a board of directors. Its organizational structure is divided into global business units focused on specific therapeutic areas and regions.
Top Products and Market Share
Key Offerings
- Dupixent: A biologic medicine used to treat atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Competitors: Amgen's Tezspire, AbbVie's Rinvoq. Revenue estimated around $10B annually.
- Lantus: A long-acting insulin analog used to treat diabetes. Biosimilar competition exists. Competitors: Novo Nordisk's Tresiba, Eli Lilly's Basaglar.
- Polio/Pertussis/Hib Vaccines: Sanofi Pasteur is a major supplier of vaccines for polio, pertussis (whooping cough), and Haemophilus influenzae type b (Hib). Competitors: GSK, Merck.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Growth is driven by an aging population, increasing prevalence of chronic diseases, and technological advancements.
Positioning
Sanofi ADR is a diversified global healthcare leader with a strong presence in pharmaceuticals and vaccines. Its competitive advantages include a broad product portfolio, global reach, and R&D capabilities.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be over $1 trillion. Sanofi ADR is positioned to capture a significant portion of this TAM through its diverse product offerings and global presence.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong R&D capabilities
- Global presence
- Established brand reputation
- Leading position in vaccines
Weaknesses
- Reliance on key products
- Exposure to patent expirations
- Integration challenges from acquisitions
- Competition from generic drugs
- Complex regulatory environment
Opportunities
- Development of innovative therapies
- Expansion into emerging markets
- Strategic acquisitions and partnerships
- Growth in vaccine demand
- Personalized medicine
Threats
- Generic competition
- Pricing pressures
- Regulatory changes
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
- NVS
- LLY
- ABBV
- AZN
Competitive Landscape
Evaluate Sanofi ADRu2019s advantages and disadvantages compared to its competitors.
Major Acquisitions
Translate Bio
- Year: 2021
- Acquisition Price (USD millions): 3200
- Strategic Rationale: Enhance mRNA technology capabilities for vaccine and therapeutic development.
Growth Trajectory and Initiatives
Historical Growth: Discuss Sanofi ADR's growth trends over the past years.
Future Projections: Provide projections for Sanofi ADR's future growth based on analyst estimates.
Recent Initiatives: Highlight recent strategic initiatives undertaken by Sanofi ADR.
Summary
Sanofi ADR is a well-established global pharmaceutical company with a diversified portfolio and strong vaccine business. The company benefits from innovative therapies like Dupixent. However, it faces generic competition and pricing pressures. Strategic acquisitions and R&D are vital for sustaining growth and addressing future challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share values may not add up to 100% due to rounding and exclusion of smaller market participants. Financial metrics are not live and are based on example data; always refer to the company's official reports for accurate figures. Future market conditions or company strategies could influence the presented rating.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sanofi ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2002-07-01 | CEO & Director Mr. Paul Hudson | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 82878 | Website https://www.sanofi.com |
Full time employees 82878 | Website https://www.sanofi.com | ||
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as an strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incor
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.